$XOMA
XOMA Royalty Corp

2023 Q2 Form 10-Q Financial Statement

#000155837023008670 Filed on May 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $1.658M $437.0K
YoY Change 68.67% -85.93%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.777M $6.196M
YoY Change 1.17% 21.11%
% of Gross Profit
Research & Development $39.00K $54.00K
YoY Change -2.5% -3.57%
% of Gross Profit
Depreciation & Amortization $224.0K $226.0K
YoY Change 22300.0% 11200.0%
% of Gross Profit
Operating Expenses $7.615M $10.61M
YoY Change 32.43% 105.09%
Operating Profit -$5.957M -$10.17M
YoY Change 24.96% 392.49%
Interest Expense $557.0K $357.0K
YoY Change 860.34% -269.19%
% of Operating Profit
Other Income/Expense, Net $557.0K $357.0K
YoY Change 474.23% -266.05%
Pretax Income -$5.400M -$9.813M
YoY Change 15.63% 330.39%
Income Tax
% Of Pretax Income
Net Earnings -$5.400M -$9.813M
YoY Change 15.63% 330.39%
Net Earnings / Revenue -325.69% -2245.54%
Basic Earnings Per Share -$0.59 -$0.98
Diluted Earnings Per Share -$0.59 -$0.98
COMMON SHARES
Basic Shares Outstanding 11.46M 11.46M
Diluted Shares Outstanding 11.47K 11.46K

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $31.77M $44.61M
YoY Change -62.05% -49.5%
Cash & Equivalents $31.40M $44.30M
Short-Term Investments $320.0K $311.0K
Other Short-Term Assets $799.0K $456.0K
YoY Change -23.98% -63.4%
Inventory
Prepaid Expenses
Receivables $901.0K $6.000K
Other Receivables $4.958M $0.00
Total Short-Term Assets $38.42M $45.07M
YoY Change -55.97% -49.7%
LONG-TERM ASSETS
Property, Plant & Equipment $5.000K $6.000K
YoY Change -50.0% -50.0%
Goodwill
YoY Change
Intangibles $14.70M $14.93M
YoY Change
Long-Term Investments
YoY Change
Other Assets $283.0K $260.0K
YoY Change 8.85% -13.62%
Total Long-Term Assets $87.24M $88.59M
YoY Change 30.28% 27.38%
TOTAL ASSETS
Total Short-Term Assets $38.42M $45.07M
Total Long-Term Assets $87.24M $88.59M
Total Assets $125.7M $133.7M
YoY Change -18.52% -16.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $740.0K $437.0K
YoY Change -35.82% -44.47%
Accrued Expenses $1.950M $6.196M
YoY Change 68.25% 497.49%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.087M $10.09M
YoY Change -15.87% 27.93%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $8.450M $9.044M
YoY Change -22.06% -20.29%
Total Long-Term Liabilities $8.450M $9.044M
YoY Change -22.06% -20.29%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.087M $10.09M
Total Long-Term Liabilities $8.450M $9.044M
Total Liabilities $15.54M $19.14M
YoY Change -19.36% -0.51%
SHAREHOLDERS EQUITY
Retained Earnings -$1.198B -$1.192B
YoY Change 2.16% 2.11%
Common Stock $86.00K $86.00K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $110.1M $114.5M
YoY Change
Total Liabilities & Shareholders Equity $125.7M $133.7M
YoY Change -18.52% -16.02%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income -$5.400M -$9.813M
YoY Change 15.63% 330.39%
Depreciation, Depletion And Amortization $224.0K $226.0K
YoY Change 22300.0% 11200.0%
Cash From Operating Activities -$7.208M -$4.924M
YoY Change 66.97% 388.01%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$4.482M -$7.234M
YoY Change 44.68%
Cash From Investing Activities -$4.482M -$7.234M
YoY Change 44.68%
FINANCING ACTIVITIES
Cash Dividend Paid $1.368M
YoY Change 0.0%
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.165M -1.368M
YoY Change 2.73% 86.12%
NET CHANGE
Cash From Operating Activities -7.208M -4.924M
Cash From Investing Activities -4.482M -7.234M
Cash From Financing Activities -1.165M -1.368M
Net Change In Cash -12.85M -13.53M
YoY Change 135.83% 100.56%
FREE CASH FLOW
Cash From Operating Activities -$7.208M -$4.924M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 xoma Accrued Preferred Stock Dividend Current
AccruedPreferredStockDividendCurrent
1368000
CY2022Q4 xoma Accrued Preferred Stock Dividend Current
AccruedPreferredStockDividendCurrent
1368000
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-50000
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-48000
CY2023Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-437000
CY2022Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-357000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
40000
CY2023Q1 xoma Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
6127000
CY2022Q4 xoma Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
2918000
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000791908
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-39801
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
XOMA Corporation
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
52-2154066
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
2200 Powell Street
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 310
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Emeryville
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94608
CY2023Q1 dei City Area Code
CityAreaCode
510
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
204-7200
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
11461068
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44300000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57826000
CY2023Q1 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
311000
CY2022Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
335000
CY2023Q1 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
6000
CY2022Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
1000
CY2022Q4 xoma Rights Receivable Current
RightsReceivableCurrent
2366000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
456000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
725000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
45073000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
61253000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
67000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
29000
CY2023Q1 xoma Long Term Rights Receivable Non Current
LongTermRightsReceivableNonCurrent
73333000
CY2022Q4 xoma Long Term Rights Receivable Non Current
LongTermRightsReceivableNonCurrent
63683000
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
14925000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
15150000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
260000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
260000
CY2023Q1 us-gaap Assets
Assets
133664000
CY2022Q4 us-gaap Assets
Assets
140382000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
437000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
524000
CY2023Q1 xoma Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
6127000
CY2022Q4 xoma Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
2918000
CY2023Q1 xoma Contingent Consideration Under Purchase Agreements
ContingentConsiderationUnderPurchaseAgreements
125000
CY2022Q4 xoma Contingent Consideration Under Purchase Agreements
ContingentConsiderationUnderPurchaseAgreements
75000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
69000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
34000
CY2023Q1 us-gaap Deferred Income Current
DeferredIncomeCurrent
1968000
CY2022Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
1899000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
10094000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6818000
CY2023Q1 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
9044000
CY2022Q4 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
9550000
CY2023Q1 us-gaap Liabilities
Liabilities
19138000
CY2022Q4 us-gaap Liabilities
Liabilities
16368000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.05
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.05
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0075
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0075
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
277333332
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
277333332
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11460968
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11460968
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11454025
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11454025
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
86000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
86000
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1306596000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1306271000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1192205000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1182392000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
114526000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
124014000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
133664000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
140382000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2750000
CY2023Q1 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
437000
CY2022Q1 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
357000
CY2023Q1 us-gaap Revenues
Revenues
437000
CY2022Q1 us-gaap Revenues
Revenues
3107000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
54000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
56000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6196000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5116000
CY2023Q1 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
4132000
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
225000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
10607000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
5172000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10170000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2065000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
357000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-215000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-9813000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9813000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2280000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2280000
CY2023Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
1368000
CY2022Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
1368000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11181000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-11181000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3648000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-3648000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.98
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.98
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11460
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11460
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11330
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11330
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
124014000
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
123000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1570000
CY2023Q1 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
1368000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-9813000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
114526000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
141876000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
633000
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
85000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
978000
CY2022Q1 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
1368000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2280000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
139924000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-9813000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-2280000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1570000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
978000
CY2023Q1 xoma Defined Contribution Plan Issuance Of Common Stock For Services Or Claims
DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims
123000
CY2022Q1 xoma Defined Contribution Plan Issuance Of Common Stock For Services Or Claims
DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims
85000
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
225000
CY2023Q1 us-gaap Depreciation Nonproduction
DepreciationNonproduction
1000
CY2022Q1 us-gaap Depreciation Nonproduction
DepreciationNonproduction
2000
CY2023Q1 xoma Operating Lease Payments Non Cash
OperatingLeasePaymentsNonCash
-47000
CY2022Q1 xoma Operating Lease Payments Non Cash
OperatingLeasePaymentsNonCash
-42000
CY2023Q1 us-gaap Equity Securities Fv Ni Realized Gain Loss
EquitySecuritiesFvNiRealizedGainLoss
-24000
CY2022Q1 us-gaap Equity Securities Fv Ni Realized Gain Loss
EquitySecuritiesFvNiRealizedGainLoss
-227000
CY2023Q1 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
5000
CY2022Q1 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-184000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-269000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-204000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3122000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
45000
CY2022Q1 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-91000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4924000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1009000
CY2023Q1 us-gaap Payment For Contingent Consideration Liability Investing Activities
PaymentForContingentConsiderationLiabilityInvestingActivities
9600000
CY2022Q1 us-gaap Payment For Contingent Consideration Liability Investing Activities
PaymentForContingentConsiderationLiabilityInvestingActivities
5000000
CY2023Q1 xoma Receipts Related To Purchase Of Royalty Rights And Other Commercial Payment Rights
ReceiptsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights
2366000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7234000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5000000
CY2023Q1 us-gaap Payments Of Dividends
PaymentsOfDividends
1368000
CY2022Q1 us-gaap Payments Of Dividends
PaymentsOfDividends
1368000
CY2022Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1606000
CY2022Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
973000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1368000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-735000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13526000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6744000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57826000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
95377000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
44300000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
88633000
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
95000
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
85000
CY2023Q1 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
1368000
CY2022Q1 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
1368000
CY2023Q1 xoma Estimated Fair Value Of Contingent Consideration Under Purchase Agreements
EstimatedFairValueOfContingentConsiderationUnderPurchaseAgreements
50000
CY2023Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. Description of Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">XOMA, a Delaware corporation, is a biotech royalty aggregator with a sizable portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company’s portfolio was built through the acquisition of rights to future milestones and royalties that the Company has made since the royalty aggregator business model was implemented in 2017 combined with out-licensing its proprietary products and platforms from its legacy discovery and development business. The Company’s drug royalty aggregator business is primarily focused on early to mid-stage clinical assets primarily in Phase 1 and 2 with significant commercial sales potential that are licensed to large-cap partners. The Company expects that most of its future revenue will be based on payments the Company may receive for milestones and royalties related to these programs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Financial Condition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has incurred significant operating losses and negative cash flows from operations since its inception. As of March 31, 2023, the Company had cash and cash equivalents of $44.3 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based on the Company’s current cash balance and its ability to control discretionary spending, such as milestone and royalty acquisitions, the Company has evaluated and concluded its financial condition is sufficient to fund its planned operations and commitments and contractual obligations for a period of at least one year following the date that these condensed consolidated financial statements are issued.</p>
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44300000
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, revenue recognized under the units-of-revenue method, royalty and commercial payment receivables, intangible assets, legal contingencies, contingent consideration and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Actual results may differ significantly from these estimates, such as the Company’s amortization of the payments received from HCRP. Under the contracts with HCRP, the amortization for the reporting period is calculated based on the payments expected to be made by the licensees to HCRP over the term of the arrangement. Any changes to the estimated payments by the licensees to HCRP can result in a material adjustment to revenue previously reported.</p>
CY2023Q1 us-gaap Cash
Cash
3700000
CY2023Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
40600000
CY2022Q4 us-gaap Cash
Cash
27500000
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
30300000
CY2022Q4 us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P17Y
CY2023Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Concentration of Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash, cash equivalents and receivables are financial instruments which potentially subject the Company to concentrations of credit risk, as well as liquidity risk. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company maintains cash balances at commercial banks. Balances commonly exceed the amount insured by the FDIC. The Company has not experienced any losses in such accounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">SVB was closed on March 10, 2023 by the California Department of Financial Protection and Innovation, which appointed the FDIC as receiver. At the time of closing, the Company maintained approximately $4.5 million of its cash and cash equivalents in accounts with SVB. On March 12, 2023, the U.S. Treasury, Federal Reserve, and FDIC announced that depositors would have access to all of their money starting March 13, 2023. The Company had full access to the $3.7 million cash and cash equivalents held at SVB as of March 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business but does not generally require collateral on receivables. For the three months ended March 31, 2023, one </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">partner represented 100% of total revenues. For the three months ended March 31, 2022, three partners represented 64%, 24% and 11% of total revenues, respectively. There was no trade receivables, net balance as of March 31, 2023 and December 31, 2022. </p>
CY2023Q1 xoma Cash And Cash Equivalents On Deposit At Financial Institution In Receivership
CashAndCashEquivalentsOnDepositAtFinancialInstitutionInReceivership
4500000
CY2023Q1 xoma Cash And Cash Equivalents On Deposit At Financial Institution In Receivership
CashAndCashEquivalentsOnDepositAtFinancialInstitutionInReceivership
3700000
CY2023Q1 us-gaap Receivables Long Term Contracts Or Programs
ReceivablesLongTermContractsOrPrograms
0
CY2022Q4 us-gaap Receivables Long Term Contracts Or Programs
ReceivablesLongTermContractsOrPrograms
0
CY2023Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
15247000
CY2023Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
322000
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
14925000
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
15247000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
97000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
15150000
CY2023Q1 us-gaap Finite Lived Intangible Assets Remaining Amortization Period1
FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
P16Y8M12D
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
673000
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
897000
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
897000
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
897000
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
897000
CY2023Q1 xoma Finite Lived Intangible Asset Expected Amortization Through Year Five
FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive
4261000
CY2023Q1 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
4132000
CY2023Q1 xoma Accrued Salaries And Employee Benefits Current
AccruedSalariesAndEmployeeBenefitsCurrent
1087000
CY2022Q4 xoma Accrued Salaries And Employee Benefits Current
AccruedSalariesAndEmployeeBenefitsCurrent
1449000
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
504000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
867000
CY2023Q1 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
304000
CY2022Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
562000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
100000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-9813000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2280000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11181000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-11181000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3648000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-3648000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11460
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11460
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11330
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11330
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.98
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.98
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6557000
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5706000
CY2023Q1 xoma Rights Receivable Current
RightsReceivableCurrent
0
CY2022Q4 xoma Rights Receivable Current
RightsReceivableCurrent
2400000
CY2023Q1 xoma Long Term Rights Receivable Non Current
LongTermRightsReceivableNonCurrent
73300000
CY2022Q4 xoma Long Term Rights Receivable Non Current
LongTermRightsReceivableNonCurrent
63700000
CY2022Q4 xoma Rights Receivable Current
RightsReceivableCurrent
2366000
CY2022Q4 xoma Long Term Rights Receivable Non Current
LongTermRightsReceivableNonCurrent
63683000
CY2023Q1 xoma Long Term Rights Receivable Non Current
LongTermRightsReceivableNonCurrent
73333000
CY2023Q1 xoma Operating Leases Number Of Leased Facilities
OperatingLeasesNumberOfLeasedFacilities
1
CY2023Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5M
CY2023Q1 xoma Lessee Operating Lease Modification Adjustment To Right Of Use Asset
LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset
100000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
69000000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
34000000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
48000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
44000
CY2023Q1 us-gaap Variable Lease Cost
VariableLeaseCost
5000
CY2022Q1 us-gaap Variable Lease Cost
VariableLeaseCost
3000
CY2023Q1 us-gaap Lease Cost
LeaseCost
53000
CY2022Q1 us-gaap Lease Cost
LeaseCost
47000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
52000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
50000
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y3M29D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y2M1D
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0551
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0551
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
11177
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
11177
CY2023Q1 xoma Contractual Obligation Estimated Milestone Payments
ContractualObligationEstimatedMilestonePayments
6300000
CY2023Q1 xoma Contractual Obligation Estimated Milestone Payments Number Of Products
ContractualObligationEstimatedMilestonePaymentsNumberOfProducts
1
CY2021Q2 xoma Number Of Arbitration Proceedings Initiated
NumberOfArbitrationProceedingsInitiated
1
CY2023Q1 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
4100000
CY2023Q1 us-gaap Share Price
SharePrice
18.66
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
12.64
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2025542
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
20.24
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y1M6D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
10804000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
725000
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
23.74
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
43998
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
38.68
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2706544
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
20.88
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M2D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
15134000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1773379
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
19.37
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y5M1D
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
13914000
CY2023Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2000000.0
CY2023Q1 xoma Accrued Retention Bonus
AccruedRetentionBonus
100000
CY2022Q4 xoma Accrued Retention Bonus
AccruedRetentionBonus
100000
CY2022Q1 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
CY2023Q1 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
CY2023Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
5900000
CY2023Q1 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2023Q1 us-gaap Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit
SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit
0
CY2023Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0

Files In Submission

Name View Source Status
xoma-20230331_def.xml Edgar Link unprocessable
xoma-20230331_cal.xml Edgar Link unprocessable
0001558370-23-008670-index-headers.html Edgar Link pending
0001558370-23-008670-index.html Edgar Link pending
0001558370-23-008670.txt Edgar Link pending
0001558370-23-008670-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
xoma-20230331.xsd Edgar Link pending
xoma-20230331x10q.htm Edgar Link pending
xoma-20230331xex10d7.htm Edgar Link pending
xoma-20230331xex31d1.htm Edgar Link pending
xoma-20230331xex31d2.htm Edgar Link pending
xoma-20230331xex32d1.htm Edgar Link pending
xoma-20230331_lab.xml Edgar Link unprocessable
xoma-20230331_pre.xml Edgar Link unprocessable
xoma-20230331x10q_htm.xml Edgar Link completed